
|Articles|November 13, 2012
GALILEO: Aflibercept provides marked improvement in visual acuity in results from follow-up to 76 weeks
Intravitreal injection of aflibercept provides marked improvement in visual acuity in treatment-naive eyes with macular edema secondary to central retinal vein occlusion in results from follow-up to 76 weeks in the phase III GALILEO study.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Tensions rise between STAAR and Broadwood as proposed Alcon deal nears vote
2
EyePoint Pharmaceuticals details phase 3 program evaluating vorolanib intravitreal insert (DURAVYU) for DME
3
Ophthalmic innovation by the decades: The 2010s
4
AAO 2025: Insights on the PULSAR extension study
5